Scientific Reports · 2019 · 73 citations · 24 references
MedicineGeneticsOncologyCancer EpidemiologyCancer GeneticsMolecular OncologyCancer Burden AssessmentCancer GenomicsCancer PrevalenceCancer Survival AnalysisMalignant NeoplasmsMolecular Tumor ProfilingHazard Ratio ModelingMutationResponse To ImmunotherapySomatic MutationsTumor Aggressiveness AssessmentTumor Mutation Burden AssessmentTumor Mutational BurdenTumor Mutational Burden Assessment
Tumor mutational burden correlates with improved survival and immunotherapy response in some malignancies, and with tumor aggressiveness in others. To study the link between mutational burden and survival, we analyzed survival effects of tumor exonic missense mutation burden (TEMMB) across 6947 specimens spanning 31 cancers which have undergone whole exome sequencing as part of TCGA. We adjusted TEMMB for age, sex, stage, and recruitment center, and computed Cox-proportional models of TEMMB survival effects. We assigned a recurrence score (RS) to each cohort, defining RS as the burden of recurrent mutations exceeding 1% population prevalence. High TEMMB was associated with improved survival in cutaneous melanoma: hazard ratio (HR) = 0.71 [0.60-0.85], p = 0.0002, urothelial bladder carcinoma: HR = 0.74 [0.59-0.93], p = 0.01, and ovarian carcinoma: HR = 0.80 [0.70-0.93], p = 0.003. High TEMMB was associated with decreased survival in colorectal adenocarcinoma: HR = 1.32 [1.00-1.74], p < 0.05. We identified that TEMMB survival effects were governed by the balance of recurrent and non-recurrent mutations. In cancers with a low RS, high TEMMB was correlated with better survival outcomes (r = 0.49, p = 0.02). In conclusion, TEMMB effects on survival depend on recurrent mutation enrichment; tumor types that are highly enriched in passenger mutations show a survival benefit in the setting of high tumor mutational burden.
24
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov, Serena Nik‐Zainal, David C. Wedge et al. · Nature · 2013 · 10.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text
Medicine, Immunology, Oncology +17
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · Genome Medicine · 2017 · 3.7K citations · Full text
Medicine, Cancer Biology, Oncology +17